Immudex ApSAktiv

Description of key activities of the companyThe main activities of Immudex are to provide MHC Dextramer® reagents and services for improved cellular immune monitoring to be used in research, clinical development and patient monitoring. The Company has during the fiscal year had the following focus areas: i. Increase sales of clinical-grade Dextramer (GMP) reagents to biophama companies engaged in T-cell therapy development ii. Increase output of new products and services by investing in more R&D activities, and we launched several new products in the year iii. Expand commercial activities The year was another difficult year as many of our biopharma companies experienced slow down in their pipelines due to lack of financing. We saw therefore a low increase in sales. Immudex continued to invest significant resources in 1) the development of new Dextramer® reagents, 2) in expanding commercial activities 3) maintaining and protecting existing patent portfolio. In the next financial year, a continued expansion of Immudex’ product portfolio will take place. Immudex is entering new clinical application areas, such as CAR-T, Autoimmunity, to continue to expand the available markets for the company.

Uddrag af ledelsesberetningen i den seneste årsrapport.